Bill Text: CA AB1842 | 2023-2024 | Regular Session | Amended
Bill Title: Health care coverage: Medication-assisted treatment.
Spectrum: Partisan Bill (Democrat 2-0)
Status: (Enrolled) 2024-08-29 - Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 75. Noes 0.). [AB1842 Detail]
Download: California-2023-AB1842-Amended.html
Amended
IN
Senate
August 22, 2024 |
Amended
IN
Senate
May 20, 2024 |
Introduced by Assembly Member Reyes (Coauthor: Assembly Member Arambula) |
January 16, 2024 |
LEGISLATIVE COUNSEL'S DIGEST
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: YESBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 1342.75 is added to the Health and Safety Code, to read:1342.75.
(a) Notwithstanding any other law, a group or individual health care service plan offering an outpatient prescription drug benefit shall provide coverage for at least one medication approved by the United States Food and Drug Administration in each of the following categories without prior authorization, step therapy, or utilization review:SEC. 2.
Section 10123.1935 is added to the Insurance Code, to read:10123.1935.
(a) Notwithstanding any other law, a group or individual health insurer offering an outpatient prescription drug benefit shall provide coverage for at least one medication approved by the United States Food and Drug Administration in each of the following categories without prior authorization, step therapy, or utilization review:Notwithstanding any other law, a health care service plan shall not subject either of the following to prior authorization or step therapy:
(a)A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b)A buprenorphine product or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.
Notwithstanding any other law, a health insurer shall not subject either of the following to prior authorization or step therapy:
(a)A naloxone product or another opioid antagonist approved by the United States Food and Drug Administration.
(b)A buprenorphine product or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder.